GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, July 24, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced new data from preclinical studies and previously completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results